Label Updates and Dosing Flexibility in Retinal Vascular Diseases

In this episode, “Label Updates and Dosing Flexibility in Retinal Vascular Diseases,” the panelists explore how recent label updates for aflibercept 8 mg are shaping treatment strategies and clinical decision-making across retinal vascular diseases. The expert faculty discuss the expanded dosing flexibility now supported by the aflibercept 8 mg label, including Q4-week dosing for difficult-to-treat patients and treatment intervals extending up to every 20 weeks for appropriate responders.

Throughout the discussion, the panel highlights how greater dosing flexibility has provided clinicians with additional confidence when individualizing treatment plans for patients with wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO). The expert faculty discuss how updated label guidance and supporting clinical trial data have improved their ability to manage both highly treatment-resistant patients and those who may benefit from significantly extended dosing intervals. In addition, the panel emphasizes how these updates may help support payer discussions and improve access to treatment strategies that better reflect real-world patient needs.

The panel also explores how responses to second-generation anti-VEGF therapies may vary across patients and how switching therapies can provide meaningful improvements in retinal drying and durability for select individuals. The expert faculty describe how some patients achieve substantial interval extensions while others require more frequent dosing, underscoring the heterogeneous nature of retinal vascular diseases. Overall, the discussion highlights how expanded label flexibility and multiple next-generation anti-VEGF options are allowing clinicians to tailor therapy more effectively while balancing durability, disease control, and treatment burden in clinical practice.

The next episode in this series, “Personalized Treatment with Faricimab in Retinal Vascular Diseases,” features the panelists discussing how faricimab clinical trial and real-world data are influencing treatment selection across retinal vascular diseases. The expert faculty also highlight the potential role of imaging biomarkers, therapeutic switching, and artificial intelligence in supporting more personalized retinal disease management.